Answers are grounded in this paper and cite their sources.
Background and Purpose: Clinical and non-clinical studies have demonstrated that treatment with inhibitors of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) improves the anemic condition associated with chronic kidney disease (CKD). The present study investigated whether the treatment with salmon calcitonin (sCT) would improve renal anemia in rats. Experimental Approach: Male wistar rats were orally administered with adenine (100 mg/kg/day) for 28 days to induce renal anemia. Subsequently, subcutaneous administration of sCT (20 IU/kg/day) or recombinant human erythropoietin (rhEPO) (30 IU/kg/day) was carried out for 21 days. Key Results: Adenine exposure resulted in reduced erythropoietin (EPO) serum levels, decreased total red blood cell (RBC) counts, hemoglobin (Hb), and hematocrit (Hct), accompanied by elevated serum levels of blood urea nitrogen (BUN), creatinine, PTH, and FGF23. In adenine-treated wistar rats, both sCT and rhEPO administrations significantly increased EPO serum levels, total RBC counts, Hb, and Hct, while decreasing serum BUN, creatinine, FGF23, and PTH levels. Histopathological analysis revealed characteristic kidney damage indicative of CKD in adenine-treated rats, which was notably absent in rats treated with sCT or rhEPO. Conclusions and Implications: The study concludes that sCT successfully mitigated renal anemia in rats suggesting its potential as a promising therapeutic strategy for CKD-related anemia.
No takes yet. Share an insight, caveat, or question.
Nayak et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: